Patents

US 10751412 B2: Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer

Granted
2020-08-25
Filed
2016-05-26 application 15577369
Type
Utility · 28 claims
Elsewhere
Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗

Abstract

The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Toll-like receptor 9 (TLR9) agonist that is a CpG-C type oligonucleotide, and the use of the combination therapies for the treatment of cancer.

Source: PVGPATDIS, file of 2026-04-10 (ipg200825.xml).

Assignees

AssigneeTypePlaceAlso on furp.orgSource
Merck Sharp & Dohme LLC 1,935 patentsUS company or organizationRahway, NJMERCK SHARP & DOHME CORP. SEC filer FUZZY low confidence: same name (legal endings aside), one of each nationallyPVGPATDIS, file of 2026-04-10
DYNAVAX TECHNOLOGIES CORPORATION 50 patentsUS company or organizationEmeryville, CADYNAVAX TECHNOLOGIES CORP SEC filer FUZZY low confidence: same name (legal endings aside), one of each nationallyPVGPATDIS, file of 2026-04-10

Inventors

InventorPlacePatentsPerson pageSource
Ying YuPalo Alto, CA12PVGPATDIS, file of 2026-04-10
Andrew DenkerLansdowne, PA8PVGPATDIS, file of 2026-04-10
Svetlana SadekovaPalo Alto, CA3PVGPATDIS, file of 2026-04-10
Uyen PhanPalo Alto, CA9PVGPATDIS, file of 2026-04-10
Robert A. KasteleinPalo Alto, CA43PVGPATDIS, file of 2026-04-10
David KAUFMANNorth Wales, PA3PVGPATDIS, file of 2026-04-10
Robert L. CoffmanBerkeley, CA23PVGPATDIS, file of 2026-04-10
Cristiana GuiducciBerkeley, CA14PVGPATDIS, file of 2026-04-10
Robert JanssenBerkeley, CA9PVGPATDIS, file of 2026-04-10

CPC categories

SubclassCategoryFirst groupSource
A61KPreparations for medical, dental or toiletry purposesA61K39/395PVGPATDIS, file of 2026-04-10
A61PSpecific therapeutic activity of chemical compounds or medicinal preparationsA61P35/00PVGPATDIS, file of 2026-04-10
C07KPeptidesC07K14/435PVGPATDIS, file of 2026-04-10

Cooperative Patent Classification, as currently assigned (one row per subclass).

Assignments and security interests

RecordedWhatFromToReel/frameSource
2024-04-30Security interest Security interest
Security interest
TRISALUS LIFE SCIENCES, INC. signed 2024-04-30ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP NEW YORK, NY67274/733PASDL, file of 2026-10-15
2023-01-03Merger
Merger
MERCK SHARP & DOHME CORP. signed 2022-04-07MERCK SHARP & DOHME LLC RAHWAY, NJ62264/846ECORSEXC, file of 2026-09-25
2021-10-27Name change
Change of name
SUREFIRE MEDICAL, INC. D/B/A TRISALUS LIFE SCIENCES signed 2021-09-29TRISALUS LIFE SCIENCES, INC. WESTMINSTER, CO57943/686ECORSEXC, file of 2026-09-25
2020-10-14Assignment
Assignment of assignor's interest
DYNAVAX TECHNOLOGIES CORPORATION signed 2020-07-31SUREFIRE MEDICAL, INC. D/B/A TRISALUS LIFE SCIENCES WESTMINSTER, CO54057/158ECORSEXC, file of 2026-09-25
2018-06-08Assignment
Assignment of assignor's interest
KAUFMAN, DAVID ROSS signed 2016-05-17
DENKER, ANDREW EVAN signed 2016-05-20
KASTELEIN, ROBERT A. signed 2016-05-23
PHAN, UYEN TRUONG signed 2016-05-23
SADEKOVA, SVETLANA signed 2016-05-23
YU, YING signed 2016-05-23
COFFMAN, ROBERT L. signed 2018-05-31
GUIDUCCI, CRISTIANA signed 2018-05-31
JANSSEN, ROBERT S. signed 2018-05-31
MERCK SHARP & DOHME CORP. RAHWAY, NJ
DYNAVAX TECHNOLOGIES CORPORATION BERKELEY, CA
46328/7ECORSEXC, file of 2026-09-25

Documents recorded with the USPTO Assignment Recordation Branch that list this patent. A security interest is a lender’s claim on the patent as collateral; a release ends it.

USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.